Aurobindo Pharma will develop complex products and expand its global footprint



Aurobindo Pharma remains focused on developing complex and differentiated products across multiple areas including oncology, hormonal products, biosimilars, depot injections and vaccines to drive the next phase of growth, according to its annual report for 2021- 22.

The Hyderabad-based company also said it is in the process of commissioning capabilities in some of the complex therapeutic areas, adding that it is committed to expanding in its key geographies of the United States, Europe and other growing markets.

“In the United States, approximately 220 abbreviated new drug applications (ANDAs) are awaiting final approval. With the easing of the pandemic situation, your company will resume its development trajectory, with emphasis on developing a line of complicated injectable products,” he informed the shareholders. .

In Europe, the company has filed applications for 58 products and is awaiting approval, the pharmaceutical major said.

In addition, nearly 200 products are in development in the general oral/general/oncology product categories, which will be launched in the next two to three years.

The pharmaceutical company is also building a dedicated injectables facility for Europe and growing markets to strengthen its presence in the hospital segment.

The facility will begin filing new injectables in FY23 with earliest possible commercialization in FY24, he added.

Aurobindo Pharma Vice President and General Manager K Nithyananda Reddy said the company has been steadily increasing its presence in China, which is one of the biggest healthcare markets in the world, in addition to being a dominant supply base.

“We are setting up an oral formulation factory in China and plan to meet our international demand apart from the domestic contribution. We have started local manufacturing in this country from January 2022 and aim to transfer 30 products from India to China,” he noted.

Of those, two have been approved, and the company expects another 10 to 15 products to receive approval this year, Reddy said.

“We also intend to transfer a few products from Europe to the Chinese factory. With a total target of reaching 40 products in China, if we are successful in achieving our plans, there should be a significant increase in our margins. on turnover and net income. he said.

The company would also continue to lead its injectables business where it envisions strong growth and healthy margins, as well as a working model that prioritizes adding value, he added.

Additionally, the growth of the biosimilar portfolio has gained steady momentum, Reddy said.

“In FY22, we filed two oncology biosimilars with the European Medicines Agency. optimistic about new revenue streams starting in the next 1-2 years,” he added.

Reddy said that in India he was constantly working on the opportunities offered by the government’s Production Linked Incentive (PLI) scheme, penicillin and related fields with very attractive prospects.

“We have initiated capacity building in these areas and invested this year (FY22) Rs 2,677.7 million and the total capital for this project is expected to be around Rs 18,500 million to Rs 19,000 million which will help us significantly improve our upstream integration, make our production value chain more resilient and improve cost control and sustainable profit margins,” he said.

Reddy noted that his strong background in generic formulations has created an overreliance on raw material supply, input prices and logistics performance – all of which are factors beyond his control.

“Unpredictability in any of these dimensions has the potential to corrode overall growth. We’re keen to moderate that impact over time,” he said.

(Only the title and image of this report may have been edited by Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Comments are closed.